Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients. Issue 3 (March 2016)

• Record Type: Journal Article
• Authors: Muduma, Gorden; Odeyemi, Isaac; Smith-Palmer, Jayne; Pollock, Richard
• Is Part Of: Advances in therapy. Volume 33:Issue 3(2016)
• Page Start: 345
• Page End: 356
• Publication Date: 2016-03
• Subjects: Burden -- Cost -- Graft rejection -- Nephrology -- Renal transplant; Diagnosis -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1007/s12325-016-0292-y
• Languages: English
• ISSNs: 0741-238X

Abstract

Abstract Antibody-mediated rejection (AbMR) is a leading cause of late graft loss in kidney transplant recipients, accounting for up to 60% of late graft failures. AbMR manifests as two distinct phenotypes: the first occurs in the immediate post-transplant period in sensitized patients; the second occurs in the late post-transplant period and has been associated with non-adherence to immunosuppression. The present review summarizes the current treatment options for AbMR, its clinical and economic burden, and approaches for reducing the risk of AbMR. While AbMR is typically refractory to treatment with corticosteroids, there are numerous other approaches focused on removal, inhibition or neutralization of donor-specific antibodies, or inhibition of complement-mediated allograft damage. AbMR treatment is generally expensive with one US study reporting costs of USD 49, 000–155, 000 per episode. However, leaving AbMR untreated puts patients at high risk of capillaritis, microangiopathy, necrosis and graft failure, which may ultimately result in much greater costs associated with a return to dialysis. Given the barriers to treatment, which include the high cost and the fact that pharmacologic treatments are currently used off-label, prevention of AbMR is important, with improvement in patient adherence to immunosuppression a key strategic approach that may be worthy of further evaluation. Funding : Astellas Pharma EMEA Limited.